Adjuvant donafenib plus sintilimab therapy for hepatocellular carcinoma at high risk of recurrence after resection: a retrospective cohort study
BackgroundHepatocellular carcinoma (HCC) carries a high recurrence risk after curative resection, yet effective adjuvant strategies remain lacking. Although donafenib plus anti-PD-1 monoclonal antibodies has shown efficacy in advanced HCC, the effectiv…